PT - JOURNAL ARTICLE AU - Dana Albon AU - Lacrecia Thomas AU - Lindsay Hoberg AU - Sophia Stamper AU - Lindsay Somerville AU - Prigi Varghese AU - Ella Balasa AU - Matthew Roman AU - Maria T Britto AU - Melanie Miner AU - Emily Gehring AU - Clifford Gammon AU - Raouf S Amin AU - Michael Seid AU - Mike Powers ED - , TI - Cystic fibrosis learning network telehealth innovation lab during the COVID-19 pandemic: a success QI story for interdisciplinary care and agenda setting AID - 10.1136/bmjoq-2022-001844 DP - 2022 May 01 TA - BMJ Open Quality PG - e001844 VI - 11 IP - 2 4099 - http://bmjopenquality.bmj.com/content/11/2/e001844.short 4100 - http://bmjopenquality.bmj.com/content/11/2/e001844.full SO - BMJ Open Qual2022 May 01; 11 AB - Introduction The Cystic Fibrosis Foundation chronic care guidelines recommend monitoring clinical status of a patient with cystic fibrosis (CF) through quarterly interdisciplinary visits. At the beginning of the COVID-19 pandemic, the Cystic Fibrosis Learning Network (CFLN) designed and initiated a telehealth (TH) innovation lab (TH ILab) to support transition from the classic CF care model of quarterly in-person office visits to a care model that included TH.Aim The specific aims of the TH ILab were to increase the percentage of virtual visits with interdisciplinary care (IDC) from 60% to 85% and increase the percentage of virtual visits in which patients and families participated in shared agenda setting (AS) from 52% to 85% by 31 December 2020.Methods The model for improvement methodology was used to determine the ILab aims, theory, interventions and measures. In the testing phase of the ILab, data related to process and outcome measures as well as learnings from plan–do–study–act cycles were collected, analysed and shared weekly with the TH ILab teams. Participating centres created processes for IDC and AS for TH visits and developed and shared quality improvement tools specific to their local context with other centres during the ILab weekly meetings and via a secure CFLN-maintained platform.Results Both specific aims were achieved ahead of the expected target date. By August 2020, 85% of the TH ILab visits provided IDC and 92% of patients were seen for CF care by teams from the TH ILab that participated in AS.Conclusion Shared learning through a collaborative, data-driven process in the CFLN TH ILab rapidly led to standardised TH IDC and AS, which achieved reliable and sustainable processes which could be reproduced by other networks.Data sharing not applicable as no datasets were generated and/or analysed for this study. N/A.